Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company, has announced the initiation of a Phase 1 study for RT-114, an oral bispecific GLP-1/GLP-2 receptor agonist, aimed at treating obesity. This trial is expected to begin in the second half of 2025. At the ENDO 2025 conference, Rani presented preclinical data demonstrating the bioequivalence of RT-114 when delivered orally via the RaniPill in comparison to subcutaneous injections in canines. This development marks a significant step forward in the clinical evaluation of RT-114 as a potential first-in-class oral therapy for obesity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.